Cell-Based Cancer Immunotherapy (STRAT-CELL) is a novel strategic research area at OUH with an overarching goal to fast-track the clinical implementation of new strategies for gene-editing of cytotoxic lymphocytes. The initiative will operate at the interface between academia and industry and support a clinical pipe-line of investigator-initiated trials.
We want to welcome you all to a symposium with three excellent international and national speakers from industry, academia, and clinic.
Venue: Radiumhospitalet, Forskningsbygget (Bygg K), Auditorium, 1st floor
10:00 – 10:30 Jeffrey Miller, University of Minnesota, Minnesota, US: “NK Biology and Orchestrating the Immune Response to Treat Cancer “
Jeff Miller is a Professor of Medicine at the University of Minnesota, and the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. His focus is on the biology of NK cells and other immune effector cells, and their use in clinical immunotherapy.
10:30 – 11:00 Jochen Buchner, Oslo University Hospital, Oslo: ”CAR T cells in Children and Young Adults with B-Cell Lymphoblastic Leukemia”.
Jochen Buchner is a Senior Consultant at the Department of Paediatric Hematology and Oncology at Rikshospitalet. He has been central in the clinical studies using Novartis’ CAR-T therapy for treatment of children and young patients with ALL.
11:00 – 11:30 Bob Valamehr, Fate Therapeutics, San Diego, US: “Pluripotent Cell-Derived T and NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy“
Bob Valamehr is the CDO at Fate Therapeutics and oversees the company’s early development activities including “off-the-shelf” cell therapy product candidates derived from Fate’s induced pluripotent stem cell platform.
Sandwiches, Coffee and refreshments will be served after the symposium
Please contact Karl-Johan Malmberg (Karolinska institutet) for more information.